Chia-Yen Dai
Kaohsiung Medical University,Taiwan
Title: The clinical impact of the end of treatment viremia in Taiwanese patients with CHC treated with DAAs
Biography
Biography: Chia-Yen Dai
Abstract
Statement of the Problem: direct-acting antivirals (DAAs) treatment is the standard of care over the world where they are avialble with high efficacy. The end-of-treatment (EOT) viremia has been encountered and the impacts are not clear. The purpose of this study is to describe the result of quantifiable HCV RNA at the EOT in Taiwan
Methodology:
In Taiwan, the National Health Insurance (NHI) reimbursed the cost of pegylated interferon plus ribavirin (PegIFN/RBV) since 2003 and direct-acting antivirals (DAAs) since January 2017. We have examined the patients who received DAAs therapy in Kaohsiung Medical University, our tertiary medical center in Kaohsiung. Patients were treated by the asunaprevir/daclatasvir, paritaprevir/ritonavir/ombitasvir/dasabuvir, Grazoprevir/ elbasvir, sofosbuvir+ribavirin, sofosbuvir/ladipasvir or glecaprevir/pibrentasvir (G/P) for standard 8-24 weeks which are available.